Two cases of successful ACT with public neoantigens from common KRAS G12D and p53 R175H mutations have demonstrated partial cancer regression for 6 months in a pancreatic and a breast cancer patient, respectively [78,79]. This evidence concerns the gene TP53 and cancer.